Roivant Sciences Ltd. (ROIV) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

11/25

Growth 2 Margin 2 Expansion 4 Platform 0 Financial 3

latest quarter score

Earnings Reports

11
Roivant (ROIV) Q1 2026: $200M Buyback and Brepocitinib Launch Set Stage for Multi-Indication Expansion
August 06, 2026
10
Roivant (ROIV) Q3 2025: Brepo 45mg Delivers 100% Response in CS, Unlocking Orphan Inflammatory Expansion
June 16, 2026
9
Roivant (ROIV) Q4 2026: $2.25B Moderna Settlement and 73% ACR20 Response in Refractory RA Signal Pipeline Inflection
May 20, 2026
9
Roivant (ROIV) Q2 2025: $4.4B Cash Secures Multi-Indication Pipeline as Brepocitinib and 1402 Data Transform Outlook
November 10, 2025
8
Roivant (ROIV) Q1 2025: $1.5B Buyback Shrinks Float 15% Ahead of Brepocitinib Readout
August 11, 2025
Roivant (ROIV) Q4 2023: $300M Debt Reduction Sharpens Pipeline Optionality
May 30, 2024
Roivant (ROIV) Q3 2024: $5.2B Cash Reserves Anchor 2025 Pipeline Milestone Wave
February 13, 2024

Browse all companies